{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T14:38:24Z","timestamp":1792852704852,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jtha.2024.12.003","type":"journal-article","created":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T22:35:39Z","timestamp":1734129339000},"page":"1146-1159","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["New targets for antithrombotic medications: seeking to decouple thrombosis from hemostasis"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6532-8440","authenticated-orcid":false,"given":"Geoffrey D.","family":"Barnes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2024.12.003_bib1","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Lozano","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2024.12.003_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.903029","article-title":"Factor XI inhibitors for prevention and treatment of venous thromboembolism: a review on the rationale and update on current evidence","volume":"9","author":"Nopp","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jtha.2024.12.003_bib3","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.thromres.2023.03.010","article-title":"Bleeding related to oral anticoagulants: trends in US Emergency Department visits, 2016-2020","volume":"225","author":"Geller","year":"2023","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2024.12.003_bib4","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/archinternmed.2010.271","article-title":"Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation","volume":"170","author":"Hansen","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jtha.2024.12.003_bib5","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1001\/jamainternmed.2018.7816","article-title":"Association of adding aspirin to warfarin therapy without an apparent indication with bleeding and other adverse events","volume":"179","author":"Schaefer","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jtha.2024.12.003_bib6","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1001\/jamainternmed.2021.1197","article-title":"Adverse events associated with the addition of aspirin to direct oral anticoagulant therapy without a clear indication","volume":"181","author":"Schaefer","year":"2021","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jtha.2024.12.003_bib7","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.jcin.2018.04.008","article-title":"A\u00a0randomized trial of the optimum duration of acoustic pulse thrombolysis procedure in acute intermediate-risk pulmonary embolism: the OPTALYSE PE trial","volume":"11","author":"Tapson","year":"2018","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jtha.2024.12.003_bib8","first-page":"5989","article-title":"Management of residual risk in chronic coronary syndromes. clinical pathways for a quality-based secondary prevention","volume":"12","author":"Giubilato","year":"2023","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jtha.2024.12.003_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2022.100175","article-title":"Reasons for nonadherence to the direct oral anticoagulant apixaban","volume":"2","author":"Tarn","year":"2023","journal-title":"JACC Adv"},{"key":"10.1016\/j.jtha.2024.12.003_bib10","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.119.005969","article-title":"Real-world adherence and persistence to direct oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis","volume":"13","author":"Ozaki","year":"2020","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jtha.2024.12.003_bib11","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.jchf.2024.04.013","article-title":"Evaluation of the hemocompatibility of the direct oral anticoagulant apixaban in left ventricular assist devices: the DOAC LVAD study","volume":"12","author":"Shah","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jtha.2024.12.003_bib12","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.12.003_bib13","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300067","article-title":"Apixaban or warfarin in patients with an On-X mechanical aortic valve","volume":"2","author":"Wang","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jtha.2024.12.003_bib14","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3109\/10409238.2015.1050550","article-title":"How it all starts: Initiation of the clotting cascade","volume":"50","author":"Smith","year":"2015","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"10.1016\/j.jtha.2024.12.003_bib15","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1182\/blood-2009-02-203604","article-title":"Factor XI contributes to thrombin generation in the absence of factor XII","volume":"114","author":"Kravtsov","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.12.003_bib16","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1182\/blood.2023020722","article-title":"Targeting factor XI and factor XIa to prevent thrombosis","volume":"143","author":"Gailani","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.12.003_bib17","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1538-7836.2005.01236.x","article-title":"Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice","volume":"3","author":"Wang","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.12.003_bib18","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1182\/blood-2016-09-742262","article-title":"Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events","volume":"129","author":"Preis","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.12.003_bib19","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1055\/s-0038-1653750","article-title":"Definition of the bleeding tendency in factor XI-deficient kindreds\u2013a clinical and laboratory study","volume":"73","author":"Bolton-Maggs","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.12.003_bib20","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1161\/ATVBAHA.113.301282","article-title":"Antithrombotic effect of antisense factor XI oligonucleotide treatment in primates","volume":"33","author":"Crosby","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2024.12.003_bib21","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1161\/CIRCULATIONAHA.122.062353","article-title":"Pharmacology and clinical development of factor XI inhibitors","volume":"147","author":"Greco","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2024.12.003_bib22","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13784","article-title":"Pharmacokinetics, pharmacodynamics, and safety of fesomersen, a novel antisense inhibitor of factor XI, in healthy Chinese, Japanese, and Caucasian volunteers","volume":"17","author":"Liu","year":"2024","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jtha.2024.12.003_bib23","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3390\/hematolrep16010016","article-title":"Drug\u2013drug interactions of FXI inhibitors: clinical relevance","volume":"16","author":"Ferri","year":"2024","journal-title":"Hematol Rep"},{"key":"10.1016\/j.jtha.2024.12.003_bib24","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI antisense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"Buller","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.12.003_bib25","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ekir.2021.11.011","article-title":"Phase 2 study of the factor XI antisense inhibitor IONIS-FXIRx in patients with ESRD","volume":"7","author":"Walsh","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.jtha.2024.12.003_bib26","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/psp4.12663","article-title":"PK\/PD modeling of FXI antisense oligonucleotides to bridge the dose-FXI activity relation from healthy volunteers to end-stage renal disease patients","volume":"10","author":"Willmann","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.jtha.2024.12.003_bib27","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.kint.2024.02.024","article-title":"A\u00a0Phase II randomized controlled trial evaluated antithrombotic treatment with fesomersen in patients with kidney failure on hemodialysis","volume":"106","author":"Winkelmayer","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.jtha.2024.12.003_bib28","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jama.2019.20687","article-title":"Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial","volume":"323","author":"Weitz","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2024.12.003_bib29","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41591-023-02794-7","article-title":"Anticoagulation with osocimab in patients with kidney failure undergoing hemodialysis: a randomized phase 2 trial","volume":"30","author":"Weitz","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jtha.2024.12.003_bib30","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2105872","article-title":"Abelacimab for prevention of venous thromboembolism","volume":"385","author":"Verhamme","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.12.003_bib31","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1182\/blood.2021011725","article-title":"The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial","volume":"138","author":"Lorentz","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.12.003_bib32","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","article-title":"Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study","volume":"399","author":"Piccini","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2024.12.003_bib33","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1161\/CIRCULATIONAHA.122.061612","article-title":"A\u00a0multicenter, phase 2, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral factor XIa inhibitor asundexian to prevent adverse cardiovascular outcomes after acute myocardial infarction","volume":"146","author":"Rao","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2024.12.003_bib34","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0140-6736(22)01588-4","article-title":"Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"400","author":"Shoamanesh","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2024.12.003_bib35","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","article-title":"Milvexian for the prevention of venous thromboembolism","volume":"385","author":"Weitz","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.12.003_bib36","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1474-4422(23)00403-9","article-title":"Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial","volume":"23","author":"Sharma","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jtha.2024.12.003_bib37","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1055\/a-2043-0346","article-title":"Factor XI inhibitors in early clinical trials: a meta-analysis","volume":"123","author":"Galli","year":"2023","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.12.003_bib38","article-title":"Asundexian versus apixaban in patients with atrial fibrillation","author":"Piccini","year":"2024","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.12.003_bib39","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1182\/blood-2018-10-880849","article-title":"MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans","volume":"133","author":"Koch","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.12.003_bib40","first-page":"6314","article-title":"Clinical pharmacology of factor XI inhibitors: new therapeutic approaches for prevention of venous and arterial thrombotic disorders","volume":"11","author":"Campello","year":"2022","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jtha.2024.12.003_bib41","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.12.003_bib42","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.kint.2021.08.028","article-title":"Anticoagulation in patients with kidney failure on dialysis: factor XI as a therapeutic target","volume":"100","author":"Eikelboom","year":"2021","journal-title":"Kidney Int"},{"issue":"Suppl 1","key":"10.1016\/j.jtha.2024.12.003_bib43","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1111\/jth.12961","article-title":"Medical device-induced thrombosis: what causes it and how can we prevent it?","volume":"13","author":"Jaffer","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.12.003_bib44","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1055\/s-0037-1603937","article-title":"Inhibition of factors XI and XII for prevention of thrombosis induced by artificial surfaces","volume":"44","author":"Tillman","year":"2018","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2024.12.003_bib45","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1161\/ATVBAHA.121.316108","article-title":"Platelet GPVI (glycoprotein VI) and thrombotic complications in the venous system","volume":"41","author":"Perrella","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2024.12.003_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107630","article-title":"Glycoprotein VI - novel target in antiplatelet medication","volume":"217","author":"Borst","year":"2021","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jtha.2024.12.003_bib47","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1474-4422(23)00427-1","article-title":"Safety and efficacy of platelet glycoprotein VI inhibition in acute ischaemic stroke (ACTIMIS): a randomised, double-blind, placebo-controlled, phase 1b\/2a trial","volume":"23","author":"Mazighi","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jtha.2024.12.003_bib48","series-title":"ACTISAVE clinical trial: efficaccy and safety of glenzocimab on top of thrombolysis with or without mechanical thrombectomy. Basel, Switzerland","author":"K\u00f6hrmann","year":"2024"},{"key":"10.1016\/j.jtha.2024.12.003_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0302897","article-title":"Targeting GPVI with glenzocimab in COVID-19 patients: results from a randomized clinical trial","volume":"19","author":"Pottecher","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.jtha.2024.12.003_bib50","unstructured":"LIBERATE. Health Research Authority."},{"key":"10.1016\/j.jtha.2024.12.003_bib51","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1001\/jamacardio.2021.0475","volume":"6","author":"Mayer","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jtha.2024.12.003_bib52","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1161\/STROKEAHA.121.037006","article-title":"Revacept, an inhibitor of platelet adhesion in symptomatic carotid stenosis: a multicenter randomized phase \u2161 trial","volume":"53","author":"Uphaus","year":"2022","journal-title":"Stroke"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624007232?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624007232?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T08:21:10Z","timestamp":1774254070000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783624007232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1538783624007232"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2024.12.003","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New targets for antithrombotic medications: seeking to decouple thrombosis from hemostasis","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2024.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}